NEW YORK (
CHANGE IN RATINGS
rated new Buy at Mizuho. $42 price target. Company is likely to retain the ESRX/MHS contract.
downgraded to hold at TheStreet Ratings.
First PacTrust Bancorp
upgraded to buy at TheStreet Ratings.
rated new Neutral at Mizuho. $45 price target. Company lacks near-term catalysts.
rated new Buy at Benchmark. Valuation call, based on a $23 price target.
rated new Hold at Think. $18 price target. Near term outlook likely to remain depressed.
rated new Buy at Nomura. $40 price target. Company can continue to grow and take market share in the display market.
upgraded at JP Morgan from Underweight to Neutral, JP Morgan said. Panel pricing appears to have bottomed.
downgraded at FBR from Market Perform to Underperform, FBR Capital Markets said. $15.50 price target. Company is facing multiple growth headwinds.
Jack in the Box
upgraded at BofA Merrill to Buy from Underperform, Bank of America Merrill Lynch said. $32 price target. Better sales and more modest food cost inflation.
downgraded at FBR from Outperform to Market Perform, FBR Capital Markets said. $9 price target. Business recovery has proven more challenging than expected.
upgraded at Argus from Hold to Buy, Argus Research said. $92 price target. Company is a market leader and emerging markets should drive growth.
rated new Neutral at Mizuho. Valuation call, based on a $99 price target.
upgraded at Morgan Stanley from Underweight to Equal-weight, Morgan Stanley said. Kyprolis will likely be approved by the FDA.
rated new Buy at Deutsche Bank. $45 price target. Shares are undervalued and have several catalysts.
rated new Outperform at Baird. $120 price target. Company is positioned well for an eventual domestic housing recovery.
downgraded at Wells Fargo to Market Perform from Outperform, Wells Fargo said. $41 to $45 valuation range. Truck cycle may be slowing more than expected.
rated new Neutral at JP Morgan. $155 price target.
rated new Neutral at Baird. Valuation call, based on a $140 price target.
upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $109 price target. CHSI acquisition should bolster growth.
rated new Overweight at JP Morgan. $167 price target. Company has a solid portfolio and management team.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Jefferies. Shares of CELG now seen reaching $75, Jefferies said. Estimates also lowered on approval delay. Buy rating.
Celgene estimates, target cut at Morgan Stanley. Shares of CELG now seen reaching $75, according to Morgan Stanley. Estimates also reduced, given disappointing trial data for Revlimid. Overweight rating.
target lowered at UBS to $40, UBS said. Macro uncertainty and associated EPS risk. Neutral rating.
numbers lowered at Citigroup. Shares of GOOG now seen reaching $740, Citigroup said. Estimates also lowered on macro uncertainty and FX weakness. Buy rating.
added to Focus List at Credit Suisse. Company is a market leader with its HiSeq machines.
added to Focus List at Credit Suisse. Company has a solid dividend and multiple potential catalysts in its pipeline.
estimates, target reduced at Keybanc. Shares of R now seen reaching $50, according to Keybanc. Estimates also cut, given a lower commercial rental outlook. Buy rating.
Ryder System numbers lowered at Jefferies. Shares of R now seen reaching $61, Jefferies said. Estimates also lowered on lower guidance. Buy rating.
target raised at Oppenheimer. Shares of T now seen reaching $40, Oppenheimer said. Positive meeting with management. Outperform rating.
numbers lowered at Jefferies. Shares of VRX now seen reaching $63, Jefferies said. Estimates also lowered on a more realistic market. Buy rating.
target raised at Oppenheimer to $48. Positive meeting with management. Outperform rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.